|
Caffey disease
(OMIM 114000), also known as infantile cortical hyperostosis, is
characterized by spontaneous episodes of subperiosteal new bone
formation typically involving the diaphyses of long bones, mandible,
and clavicles in young children. It is associated with acute
inflammation of soft tissues and can lead to profound alterations in
the shape and structure of affected bones. It often exhibits an
autosomal dominant pattern of inheritance with substantial variation
in severity.
A group headed
by Jüppner undertook genome-wide linkage studies to map the
Caffey disease gene locus in 3 unrelated families. Their search led
them to chromosome 17q21 and eventually—to their surprise—to
the COL1A1 locus, which encodes the α
1 chain of type I collagen. Affected individuals in all 3 families
had the identical mutation: an arginine to cysteine substitution at
position 836 (R836C) placing it in the carboxy portion of the triple
helical domain of the collagen molecule. About one-fifth of family
members in whom the mutation was detected had no clinical features
consistent with previous reports of reduced penetrance for the
condition.
Mutations of the
COL1A1 are typically associated with osteogenesis imperfecta
(OI) and, to a lesser extent, with Ehlers-Danlos syndrome (EDS). The
affected members of these families did not display clinical signs of
OI. They lacked gray-blue sclerae, dentinogenesis imperfecta,
premature hearing loss, and short stature. Although bone fractures
were relatively common in one family, they were considered within the
range of normal. One affected member in this family had normal bone
densitometry studies.
Several affected
family members had joint hypermobility and abnormally soft and
hyperextensible skin suggestive of mild EDS. Electron microscopy of a
skin biopsy from one of these patients revealed that collagen fibrils
varied more in size and shape and were less densely packed than
normal. Collagen biosynthetic studies of fibroblasts from this
patient showed abnormalities consistent with the presence of cysteine
residues in the mutant type I collagen chains.
Perhaps most
interesting, as addressed by both Gensure et al and in an
accompanying comment by Glorieux,1 is how one explains the
episodic nature of this condition by a mutation in an extremely
abundant structural protein present in bone and neighboring tissues
(Figure). Although both raise several interesting possibilities, they
also conceded that the question remains open and will require further
investigation.
Gensure
RC, Mäkitie O, Barclay C, et al. A novel COL1A1 mutation in
infantile cortical hyperostosis (Caffey disease) expands the spectrum
of collagen-related disorders. J Clin Invest.
2005;115:1250−1257.
Editor’s
Comment: It was not surprising to learn that OI and some forms of
EDS are allelic disorders given the overlap in some of their
features. However, it is surprising to find Caffey disease in this
group. Even though there appears to be some clinical overlap with
mild EDS, the inflammatory and episodic nature of Caffey disease
makes it quite distinct. As both Gensure and Glorieux1
point out, some of the differences in clinical phenotype may be due
to the fact that the mutation reported here does not involve a
glycine residue as do most OI mutations. Collagen glycine mutations
are thought to disrupt the formation and stability of the collagen
triple helix, which is responsible for the structural properties of
collagen. The Caffey disease mutation affects an arginine residue,
which interestingly has been reported in 2 unrelated patients with
classic EDS. As both also note, administration of prostaglandin E to
infants with congenital heart disease sometimes causes local
hyperostosis similar to episodes of Caffey disease, raising the
possibility that this substance somehow mediates the pathologic
events. If so, it remains to be determined how abnormal type I
collagen sets the stage for inflammation and reactive bone formation.
William A. Horton, MD
Reference - (linked to )
- Glorieux F. Caffey disease: An unlikely collagenapathy. J Clin Invest. 2005115:1142-1144.
|